Tamoxifen (TMX) is used worldwide as a selective estrogen receptor modifier (SERM) for women with estrogen receptor-positive breast cancer by which treatment induces high risk of massive hepatic steatosis and even NASH 22, 23. This evidence concerns the gene ESR1 and metabolic dysfunction-associated steatohepatitis.